Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic...
White lines are resistance, purple are support - Play the targets how you please... a close above 1.92 and we’ll get our trek to 5!! Accumulate while you can. Volume has been beautiful the last couple months. Looks like a solid setup, but know your risk.
Contextual immersion trading strategy idea.
Salarius Pharmaceuticals, Inc. a clinical-stage biotechnology company, develops epigenetic-based cancer treatments.
The demand for shares of the company looks higher than the supply.
This and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $1,17;
stop-loss —...
SLRX has formed a perfect bottoming pattern on the weekly chart.
Technical reasons for the trade:
→ Double bottom (and another smaller double bottom recently!)
→ Highest weekly volume ever
→ Break above the POC
→ Price still trading within the reload zone (0.618 fib)
→ Weekly price gaps above make for some nice targets
→ Clearly defined risk window
Good...
What did I missed that caused the SLRX to slid? Was there an indicator that I should've taken as an exit plan? or is there some indications that I should have taken into consideration as one of my entry criteria? Did I also missed any information I missed prior taking a position?
Recap of catalyst:
- PDUFA for Seclidemstat in P 1/2 Ewing Sarcoma scheduled on...
These are currently 4 penny stocks that I'm bullish on for a potential reentry: $MARK been beaten up alot, and I think the resistance might pop soon for a gap fill. BBI has been mostly bearish and should retrace soon for the next positive wedge. ADOM is a long hold. SLRX is one of those stocks that may be due for even another breakout. As always, please pursue at...
(NOTE: Use daily chart then move to weekly to see my thesis)
NASDAQ:SLRX
There is a strong sense of optimism for SLRX because of the PDUFA for Seclidemstat in P 1/2 Ewing Sarcoma trial this June 17, 2020. Most small bios like SLRX are typically driven by these types of updates, but it comes with a high risks that it may turn out it is not a good results. So,...
Hello,
What is SLRX?
Salarius Pharmaceuticals, Inc. a clinical-stage biotechnology company, develops epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. Salarius...
First off, please don't take anything I say seriously or as financial advice. As always, this is on an opinion based basis. That being said, SLRX have pulled a bullish run and then crash within an hour. This was likely due to some automated trigger by some large fund starting to slowly upward incremental sell at the $1.15 level or people subscribing to some sort...
First off, please don't take anything I say seriously or as financial advice. As always, this is on an opinion based basis. That being said, let me get into a few insights. SLRX had one of the biggest yearly price declines, and bearish runs. Looking at the indicators, and company activity, you can still see some potential however. Currently, I'm waiting for a gap...
First off, please don't take anything I say seriously or as financial advice. As always, this is on an opinion based basis. That being said, here are my insights: SLRX have had recent news, especially with the Flex Pharma agreement , and their expected upcoming ASCO20 Trial Poster presentation. This + the fact that it is long due for a breakout is why I AM...
First off, please don't take anything I say seriously or as financial advice. As always, this is on opinion based basis. That being said, here are a few important insights. SLRX is right due for a potential breakout or bullish run as I have said recently. I am waiting still to see what would happen, and a potential spike in growth as we can never be too sure....
